Vascarta announces NIH Phase I clinical study for sickle cell disease therapy
Summit-based clinical-stage pharmaceutical company Vascarta announced Aug. 19 that a second proof-of-concept Phase I clinical study of VAS-101 (Vasceptor; topical curcumin gel) in...